HUMAW
Humacyte, Inc.
Price Chart
Latest Quote
$0.01
+0.00 (+0.00%)
Current Price
| Previous Close | $0.01 |
| Open | $0.23 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 22,464 |
Stock Information
| Total Debt | $66.50M |
| Cash Equivalents | $48.54M |
| Revenue | $2.02M |
| Net Income | $-95.22M |
| EPS (TTM) | $-3.16 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Sales | $2.02M |
| Income | $-95.22M |
| Book/sh | $0.05 |
| Employees | 184 |
Financial Ratios
| Quick Ratio | 3.02 |
| Current Ratio | 3.93 |
| Debt/Eq | 572.10 |
Returns & Margins
| ROA | -51.48% |
| ROE | -409.47% |
| Operating Margin | -5704.04% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | 0.10 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.10 |
| SMA50 | $0.11 |
| ATR | 0.0075 |
| Shares Float | 190.57M |
| Volatility | 2.46 |
| Rel Volume | 20.00 |
Performance History
| Week | -95.27% |
| Month | -95.27% |
| Quarter | -95.27% |
| YTD | -94.91% |
| 10 Years | -94.91% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.01 | 22,464 |
| 2026-06-18 | $0.11 | 0 |
| 2026-06-17 | $0.11 | 0 |
| 2026-06-16 | $0.11 | 0 |
| 2026-06-15 | $0.11 | 0 |
| 2026-06-12 | $0.11 | 0 |
| 2026-06-11 | $0.11 | 0 |
| 2026-06-10 | $0.11 | 0 |
| 2026-06-09 | $0.11 | 0 |
| 2026-06-08 | $0.11 | 0 |
| 2026-06-05 | $0.11 | 0 |
| 2026-06-04 | $0.11 | 0 |
| 2026-06-03 | $0.11 | 0 |
| 2026-06-02 | $0.11 | 0 |
| 2026-06-01 | $0.11 | 0 |
| 2026-05-29 | $0.11 | 0 |
| 2026-05-28 | $0.11 | 0 |
| 2026-05-27 | $0.11 | 0 |
| 2026-05-26 | $0.11 | 0 |
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
đ° Latest News
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
Zacks âĸ 2026-06-19T13:30:02Z
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Zacks âĸ 2026-06-16T22:00:02Z
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses
Stocktwits âĸ 2026-06-10T22:48:30Z
Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall
MT Newswires âĸ 2026-06-10T20:51:12ZHumacyte (HUMA) Q1 2025 Earnings Transcript
Motley Fool âĸ 2026-06-01T14:38:43Z
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis Data - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-05-31T08:03:01Z
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
Insider Monkey âĸ 2026-05-19T11:08:46Z
Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ...
GuruFocus.com âĸ 2026-05-13T23:02:04ZHumacyte (HUMA) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-13T18:53:15Z
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga âĸ 2026-05-13T13:29:06Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $9,702,000 | $0 | - | - |
| Cost Of Revenue | $9,702,000 | $0 | - | - |
| Total Revenue | $2,038,000 | $0 | $0 | $0 |
| Operating Revenue | $2,038,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $11,250,000 | $9,277,000 | $6,599,000 | $6,200,000 |
| Total Expenses | $110,175,000 | $114,398,000 | $100,047,000 | $84,578,000 |
| Other Income Expense | $75,967,000 | $-29,130,000 | $-9,597,000 | $76,184,000 |
| Net Non Operating Interest Income Expense | $-8,663,000 | $-5,173,000 | $-1,132,000 | $-3,571,000 |
| Interest Expense Non Operating | $11,250,000 | $9,277,000 | $6,599,000 | $6,200,000 |
| Operating Expense | $100,473,000 | $114,398,000 | $100,047,000 | $84,578,000 |
| General And Administrative Expense | $31,171,000 | $25,799,000 | $23,497,000 | $22,883,000 |
| Other Operating Expenses | - | - | - | $-1,565,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Net Interest Income | $-8,663,000 | $-5,173,000 | $-1,132,000 | $-3,571,000 |
| Interest Income | $2,587,000 | $4,104,000 | $5,467,000 | $2,629,000 |
| Normalized Income | $-116,800,000 | $-119,571,000 | $-101,179,000 | $-88,149,000 |
| Net Income From Continuing And Discontinued Operation | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Total Operating Income As Reported | $-108,137,000 | $-114,398,000 | $-100,047,000 | $-84,578,000 |
| Net Income Common Stockholders | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Net Income | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Net Income Including Noncontrolling Interests | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Net Income Continuous Operations | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Pretax Income | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Special Income Charges | $37,202,000 | $-33,045,000 | $-9,337,000 | $75,767,000 |
| Interest Income Non Operating | $2,587,000 | $4,104,000 | $5,467,000 | $2,629,000 |
| Operating Income | $-108,137,000 | $-114,398,000 | $-100,047,000 | $-84,578,000 |
| Gross Profit | $-7,664,000 | $0 | - | - |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-98,205,000 | $-103,104,000 | $-86,861,000 | $-73,739,000 |
| Total Unusual Items | $75,967,000 | $-29,130,000 | $-9,597,000 | $76,184,000 |
| Total Unusual Items Excluding Goodwill | $75,967,000 | $-29,130,000 | $-9,597,000 | $76,184,000 |
| Reconciled Depreciation | $7,345,000 | $7,190,000 | $7,719,000 | $8,210,000 |
| EBITDA (Bullshit earnings) | $-22,238,000 | $-132,234,000 | $-96,458,000 | $2,445,000 |
| EBIT | $-29,583,000 | $-139,424,000 | $-104,177,000 | $-5,765,000 |
| Diluted NI Availto Com Stockholders | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Other Special Charges | $22,267,000 | - | $-686,000 | - |
| Restructuring And Mergern Acquisition | $-59,469,000 | $33,045,000 | $10,023,000 | $-75,767,000 |
| Gain On Sale Of Security | $38,765,000 | $3,915,000 | $-260,000 | $417,000 |
| Research And Development | $69,302,000 | $88,599,000 | $76,550,000 | $63,260,000 |
| Selling General And Administration | $31,171,000 | $25,799,000 | $23,497,000 | $22,883,000 |
| Other Gand A | $31,171,000 | $25,799,000 | $23,497,000 | $22,883,000 |
| Salaries And Wages | - | - | $-3,107,000 | $0 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,109,000 | $-52,669,000 | $13,546,000 | $116,928,000 |
| Total Assets | $116,366,000 | $137,872,000 | $128,223,000 | $204,302,000 |
| Total Non Current Assets | $48,571,000 | $90,013,000 | $44,945,000 | $50,094,000 |
| Other Non Current Assets | $881,000 | $51,460,000 | $841,000 | - |
| Current Assets | $67,795,000 | $47,859,000 | $83,278,000 | $154,208,000 |
| Other Current Assets | $3,268,000 | $2,922,000 | $2,830,000 | $2,298,000 |
| Inventory | $13,589,000 | $0 | - | - |
| Receivables | $441,000 | $0 | $0 | $31,000 |
| Accounts Receivable | $441,000 | $0 | $0 | $31,000 |
| Cash Cash Equivalents And Short Term Investments | $50,497,000 | $44,937,000 | $80,448,000 | $151,879,000 |
| Cash And Cash Equivalents | $50,497,000 | $44,937,000 | $80,448,000 | $149,772,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $64,846,000 | $16,537,000 | $18,853,000 | $50,066,000 |
| Long Term Debt And Capital Lease Obligation | $62,418,000 | $13,620,000 | $16,293,000 | $39,189,000 |
| Long Term Debt | $35,444,000 | - | $38,600,000 | $20,336,000 |
| Current Debt And Capital Lease Obligation | $2,428,000 | $2,917,000 | $2,560,000 | $10,877,000 |
| Current Debt | - | - | - | $8,571,000 |
| Other Current Borrowings | - | - | - | $8,571,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $113,257,000 | $190,541,000 | $114,677,000 | $87,374,000 |
| Total Non Current Liabilities Net Minority Interest | $94,885,000 | $170,587,000 | $96,234,000 | $67,794,000 |
| Other Non Current Liabilities | $13,075,000 | $135,298,000 | $77,227,000 | $28,605,000 |
| Derivative Product Liabilities | $19,392,000 | $21,669,000 | $2,714,000 | $0 |
| Current Liabilities | $18,372,000 | $19,954,000 | $18,443,000 | $19,580,000 |
| Payables And Accrued Expenses | $9,311,000 | $9,672,000 | $10,592,000 | $4,476,000 |
| Payables | $5,404,000 | $4,490,000 | $6,490,000 | $1,595,000 |
| Accounts Payable | $5,404,000 | $4,490,000 | $6,490,000 | $1,595,000 |
| Other Current Liabilities | - | $1,123,000 | $53,000 | - |
| Current Deferred Liabilities | - | - | - | $0 |
| Current Deferred Taxes Liabilities | - | - | - | $0 |
| Non Current Deferred Liabilities | - | - | - | - |
| Non Current Deferred Taxes Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $3,109,000 | $-52,669,000 | $13,546,000 | $116,928,000 |
| Total Equity Gross Minority Interest | $3,109,000 | $-52,669,000 | $13,546,000 | $116,928,000 |
| Stockholders Equity | $3,109,000 | $-52,669,000 | $13,546,000 | $116,928,000 |
| Retained Earnings | $-726,848,000 | $-686,015,000 | $-537,314,000 | $-426,538,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $193,000,611 | $130,027,509 | $103,673,728 | $103,229,013 |
| Share Issued | $193,000,611 | $130,027,509 | $103,673,728 | $103,229,013 |
| Tangible Book Value | $3,109,000 | $-52,669,000 | $13,546,000 | $116,928,000 |
| Invested Capital | $38,553,000 | $-52,669,000 | $13,546,000 | $145,835,000 |
| Working Capital | $49,423,000 | $27,905,000 | $64,835,000 | $134,628,000 |
| Capital Lease Obligations | $29,402,000 | $16,537,000 | $18,853,000 | $21,159,000 |
| Total Capitalization | $38,553,000 | $-52,669,000 | $13,546,000 | $137,264,000 |
| Additional Paid In Capital | $729,937,000 | $633,333,000 | $550,850,000 | $543,456,000 |
| Capital Stock | $20,000 | $13,000 | $10,000 | $10,000 |
| Common Stock | $20,000 | $13,000 | $10,000 | $10,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $26,974,000 | $13,620,000 | $16,293,000 | $18,853,000 |
| Current Capital Lease Obligation | $2,428,000 | $2,917,000 | $2,560,000 | $2,306,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,633,000 | $6,242,000 | $5,238,000 | $4,227,000 |
| Current Accrued Expenses | $3,907,000 | $5,182,000 | $4,102,000 | $2,881,000 |
| Net PPE | $47,690,000 | $38,553,000 | $44,104,000 | $50,094,000 |
| Accumulated Depreciation | $-41,332,000 | $-36,087,000 | $-31,326,000 | $-26,181,000 |
| Gross PPE | $89,022,000 | $74,640,000 | $75,430,000 | $76,275,000 |
| Leases | $27,967,000 | $27,901,000 | $27,844,000 | $26,355,000 |
| Other Properties | $58,861,000 | $44,549,000 | $45,713,000 | $47,876,000 |
| Machinery Furniture Equipment | $2,194,000 | $2,190,000 | $1,873,000 | $1,364,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-8,897,000 | $0 | - | - |
| Finished Goods | $10,122,000 | $0 | - | - |
| Work In Process | $6,541,000 | $0 | - | - |
| Raw Materials | $5,823,000 | $0 | - | - |
| Construction In Progress | - | - | $0 | $680,000 |
| Other Short Term Investments | - | - | $0 | $2,107,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-105,926,000 | $-99,694,000 | $-75,585,000 | $-72,177,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-105,042,000 | $-98,122,000 | $-73,305,000 | $-71,129,000 |
| Cash Flow From Continuing Operating Activities | $-105,042,000 | $-98,122,000 | $-73,305,000 | $-71,129,000 |
| Operating Gains Losses | $-16,493,000 | $-3,911,000 | $2,699,000 | $-411,000 |
| Investing Activities | ||||
| Capital Expenditure | $-884,000 | $-1,572,000 | $-2,280,000 | $-1,048,000 |
| Investing Cash Flow | $-884,000 | $-1,572,000 | $-173,000 | $4,845,000 |
| Cash Flow From Continuing Investing Activities | $-884,000 | $-1,572,000 | $-173,000 | $4,845,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $103,450,000 | $89,052,000 | $0 | - |
| Financing Cash Flow | $61,486,000 | $114,183,000 | $4,507,000 | $-1,446,000 |
| Cash Flow From Continuing Financing Activities | $61,486,000 | $114,183,000 | $4,507,000 | $-1,446,000 |
| Net Other Financing Charges | $-88,939,000 | $19,390,000 | $38,007,000 | - |
| Cash Dividends Paid | $0 | $0 | - | - |
| Net Preferred Stock Issuance | $56,450,000 | $43,126,000 | $0 | - |
| Preferred Stock Issuance | $56,450,000 | $43,126,000 | $0 | - |
| Net Common Stock Issuance | $47,000,000 | $45,926,000 | $0 | - |
| Common Stock Issuance | $47,000,000 | $45,926,000 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-2,754,000 | $-2,579,000 | $-34,066,000 | $-1,981,000 |
| Issuance Of Debt | $39,783,000 | $0 | - | $0 |
| End Cash Position | $50,850,000 | $95,290,000 | $80,801,000 | $149,772,000 |
| Beginning Cash Position | $95,290,000 | $80,801,000 | $149,772,000 | $217,502,000 |
| Changes In Cash | $-44,440,000 | $14,489,000 | $-68,971,000 | $-67,730,000 |
| Interest Paid Cff | $-45,000 | $0 | - | - |
| Proceeds From Stock Option Exercised | $9,991,000 | $8,320,000 | $566,000 | $535,000 |
| Net Issuance Payments Of Debt | $37,029,000 | $-2,579,000 | $-34,066,000 | $-1,981,000 |
| Net Long Term Debt Issuance | $37,029,000 | $-2,579,000 | $-34,066,000 | $-1,981,000 |
| Long Term Debt Payments | $-2,754,000 | $-2,579,000 | $-34,066,000 | $-1,981,000 |
| Long Term Debt Issuance | $39,783,000 | $0 | - | $0 |
| Net PPE Purchase And Sale | $-884,000 | $-1,572,000 | $-2,280,000 | $-1,048,000 |
| Purchase Of PPE | $-884,000 | $-1,572,000 | $-2,280,000 | $-1,048,000 |
| Change In Working Capital | $-23,395,000 | $311,000 | $6,571,000 | $1,029,000 |
| Change In Other Current Liabilities | $-44,000 | $-53,000 | $-50,000 | $-45,000 |
| Change In Payables And Accrued Expense | $-736,000 | $276,000 | $6,978,000 | $-262,000 |
| Change In Accrued Expense | $-1,709,000 | $2,238,000 | $2,167,000 | $247,000 |
| Change In Payable | $973,000 | $-1,962,000 | $4,811,000 | $-509,000 |
| Change In Account Payable | $973,000 | $-1,962,000 | $4,811,000 | $-509,000 |
| Change In Prepaid Assets | $-527,000 | $88,000 | $-388,000 | $1,364,000 |
| Change In Inventory | $-21,827,000 | $0 | - | - |
| Change In Receivables | $-261,000 | $0 | $31,000 | $145,000 |
| Changes In Account Receivables | $-261,000 | $0 | $31,000 | $145,000 |
| Other Non Cash Items | $-50,316,000 | $40,852,000 | $13,654,000 | $-74,176,000 |
| Stock Based Compensation | $9,753,000 | $6,137,000 | $6,828,000 | $6,184,000 |
| Provisionand Write Offof Assets | $8,897,000 | $0 | - | - |
| Depreciation Amortization Depletion | $7,345,000 | $7,190,000 | $7,719,000 | $8,210,000 |
| Depreciation And Amortization | $7,345,000 | $7,190,000 | $7,719,000 | $8,210,000 |
| Amortization Cash Flow | $2,017,000 | $2,086,000 | $2,060,000 | $2,059,000 |
| Amortization Of Intangibles | $2,017,000 | $2,086,000 | $2,060,000 | $2,059,000 |
| Depreciation | $5,328,000 | $5,104,000 | $5,659,000 | $6,151,000 |
| Gain Loss On Investment Securities | $-38,765,000 | $-3,915,000 | $260,000 | $-417,000 |
| Gain Loss On Sale Of PPE | $5,000 | $4,000 | $18,000 | $6,000 |
| Net Income From Continuing Operations | $-40,833,000 | $-148,701,000 | $-110,776,000 | $-11,965,000 |
| Interest Paid Supplemental Data | - | $0 | $1,613,000 | $2,668,000 |
| Net Investment Purchase And Sale | - | $0 | $2,107,000 | $5,893,000 |
| Sale Of Investment | - | $0 | $2,107,000 | $16,000,000 |
| Purchase Of Investment | - | - | $0 | $-10,107,000 |
| Change In Other Working Capital | - | - | - | $-173,000 |
| Asset Impairment Charge | - | - | - | $0 |
| Sale Of PPE | - | - | - | - |
Fetched: 2026-06-24